Überprüfung…
Automatisch übersetzt. Dosierung und Warnhinweise: bitte im englischen Original prüfen. Auf Englisch lesen
Homepage / Eingetragen in Nigeria / Dermazin Cream_

Dermazin Cream_

NAFDAC Reg.-Nr. 04-0223 Medikament

Registriert bei NAFDAC. Registrierung aktivAs of 2 November 2026 · synced automatically from official sources.
Produkt-
Dermazin Cream_
NAFDAC-Nummer
04-0223
Wirkstoff
Silver sulfadiazine
Stärke
10 mg
Form
Cream
VPE:
1 x 50 g;1 x 25 g (in Alu tubes)
Hersteller
Nicht aufgeführt
Applicant (holder)
Taylek Drug Company Limited
Approved
26 Nov 2025
Status
Active View on NAFDAC ↗
Registration valid to
25 Nov 2030
WER WARNT
None found
Community reports
None
Times checked
0

About the medicine: Silver sulfadiazine: uses, dosage and brands worldwide

What we found

  • Dermazin Cream_ is on the NAFDAC register with an active registration (04-0223). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Dermazin Cream_

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

How to take it and how often
  • Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain
  • The burn wounds are then cleansed and debrided; silver sulfadiazine cream, USP 1% is then applied under sterile conditions
  • The burn areas should be covered with silver sulfadiazine cream, USP 1% at all times
  • The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch
  • Whenever necessary, the cream should be reapplied to any areas from which it has been removed by patient activity
  • Administration may be accomplished in minimal time because dressings are not required
  • However, if individual patient requirements make dressings necessary, they may be used
  • Reapply immediately after hydrotherapy
  • Treatment with silver sulfadiazine cream, USP 1% should be continued until satisfactory healing has occurred or until the burn site is ready for grafting
  • The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs
Children

. Safety and effectiveness in children have not been established. (See CONTRAINDICATIONS )

Older adults

. Of the total number of subjects in clinical studies of silver sulfadiazine cream, USP 1% seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Talk to a doctor first if
  • Silver sulfadiazine cream, USP 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation
  • Because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, USP 1% should not be used on pregnant women approaching or at term, on premature
  • Infants, or on newborn
  • Infants during the first 2 months of life
Warnings

Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and …

Possible side effects

Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy. 1,2,3 Leukopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. An increased incidence has been seen in patients treated concurrently with cimetidine. …

Pregnancy and breastfeeding

PREGNANCY: TERATOGENIC EFFECTS: Pregnancy Category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in silver sulfadiazine cream, USP 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant women. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-06-17.

Label for silver sulfadiazine, the active ingredient registered with NAFDAC.

Check your pack of Dermazin Cream_

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

About Dermazin Cream_

What is in Dermazin Cream_?

Dermazin Cream_ contains Silver sulfadiazine (10 mg), as cream, according to its NAFDAC registration record.

Is Dermazin Cream_ registered with NAFDAC?

Yes. Dermazin Cream_ is listed on the NAFDAC register under registration number 04-0223, and its registration is active as of 2 November 2026.

Has Dermazin Cream_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Dermazin Cream_ in our automatically synced alert list.

How can I check that my pack of Dermazin Cream_ is genuine?

Run a free authenticity scan with the NAFDAC number 04-0223, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Dermazin Cream_?

Follow your prescription or the leaflet in your pack. The official label says: Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; silver sulfadiazine cream, USP 1% is then applied under sterile conditions. The burn areas should be covered with silver sulfadiazine cream, USP 1% at all times. The cream should be applied o…

What is Dermazin Cream_ used for?

Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. (Summarised from the official U.S. FDA label for silver sulfadiazine. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Dermazin Cream_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.